SEC Form 4 · accession 0002069239-26-000005
Janux Therapeutics, Inc. · JANX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Janeen Noel Doyle
Officer — Chief Corp. & Bus. Dev. Ofcr
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817713
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 2, 2026 | S | 4,059 | $14.029 | D | 75,941 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- F2The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.